Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen V Frye

Showing results (81-90 of 126) with videos related to

Pageof 13
Sort By:
Journal of Medicinal Chemistry|July 29, 2014
UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitorWeihe Zhang, Deborah DeRyckere, Debra Hunter, et al.
Epigenetics & Chromatin|October 24, 2020
The histone and non-histone methyllysine reader activities of the UHRF1 tandem Tudor domain are dispensable for the propagation of aberrant DNA methylation patterning in cancer cellsRobert M Vaughan, Ariana Kupai, Caroline A Foley, et al.
Frontiers in Oncology|February 16, 2023
MS0621, a novel small-molecule modulator of Ewing sarcoma chromatin accessibility, interacts with an RNA-associated macromolecular complex and influences RNA splicingTamara Vital, Aminah Wali, Kyle V Butler, et al.
European Journal of Medicinal Chemistry|May 23, 2013
UNC1062, a new and potent Mer inhibitorJing Liu, Weihe Zhang, Michael A Stashko, et al.
ACS Bio & Med Chem Au|April 20, 2026
Discovery of Small-Molecule Antagonists of PHF1 and 19 Demonstrates the Ligandability of PRC2 Accessory ProteinsIsabelle E Amick, Rebecca L Johnson, Jiuyang Liu, et al.
JCI Insight|May 10, 2016
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemiaKatherine A Minson, Catherine C Smith, Deborah DeRyckere, et al.
ACS Chemical Biology|January 16, 2015
Identification of a fragment-like small molecule ligand for the methyl-lysine binding protein, 53BP1Michael T Perfetti, Brandi M Baughman, Bradley M Dickson, et al.
Leukemia|September 25, 2024
MERTK inhibition selectively activates a DC - T-cell axis to provide anti-leukemia immunityJustus M Huelse, Swati S Bhasin, Kristen M Jacobsen, et al.
The Journal of Biological Chemistry|October 22, 2023
Discovery of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic approach for Alzheimer's diseaseYuhong Du, William J Bradshaw, Tina M Leisner, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's diseaseYuhong Du, William J Bradshaw, Tina M Leisner, et al.
Pageof 13

Showing results (81-90 of 126) with videos related to

Sort By:
Pageof 13
Journal of Medicinal Chemistry|July 29, 2014
UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitorWeihe Zhang, Deborah DeRyckere, Debra Hunter, et al.
Epigenetics & Chromatin|October 24, 2020
The histone and non-histone methyllysine reader activities of the UHRF1 tandem Tudor domain are dispensable for the propagation of aberrant DNA methylation patterning in cancer cellsRobert M Vaughan, Ariana Kupai, Caroline A Foley, et al.
Frontiers in Oncology|February 16, 2023
MS0621, a novel small-molecule modulator of Ewing sarcoma chromatin accessibility, interacts with an RNA-associated macromolecular complex and influences RNA splicingTamara Vital, Aminah Wali, Kyle V Butler, et al.
European Journal of Medicinal Chemistry|May 23, 2013
UNC1062, a new and potent Mer inhibitorJing Liu, Weihe Zhang, Michael A Stashko, et al.
ACS Bio & Med Chem Au|April 20, 2026
Discovery of Small-Molecule Antagonists of PHF1 and 19 Demonstrates the Ligandability of PRC2 Accessory ProteinsIsabelle E Amick, Rebecca L Johnson, Jiuyang Liu, et al.
JCI Insight|May 10, 2016
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemiaKatherine A Minson, Catherine C Smith, Deborah DeRyckere, et al.
ACS Chemical Biology|January 16, 2015
Identification of a fragment-like small molecule ligand for the methyl-lysine binding protein, 53BP1Michael T Perfetti, Brandi M Baughman, Bradley M Dickson, et al.
Leukemia|September 25, 2024
MERTK inhibition selectively activates a DC - T-cell axis to provide anti-leukemia immunityJustus M Huelse, Swati S Bhasin, Kristen M Jacobsen, et al.
The Journal of Biological Chemistry|October 22, 2023
Discovery of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic approach for Alzheimer's diseaseYuhong Du, William J Bradshaw, Tina M Leisner, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's diseaseYuhong Du, William J Bradshaw, Tina M Leisner, et al.
Pageof 13